It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma.
1. What have we learned so far from clinical trials of immune checkpoint inhibition for urothelial cancer? (0:06)
2. What have been the latest efficacy and safety findings of the JAVELIN Bladder 100 trial? (0:32)
3. How do the findings of this study compare with those of other immune checkpoint inhibitors in this treatment setting? (1:54)
4. How can we predict which patients are most likely to respond to avelumab? (2:57)
5. What lies ahead in the treatment of urothelial cancer? (4:42)
Speaker disclosure: Thomas Powles has received honoraria from AstraZeneca, Bristol-Myers Squibb, Ferring, GLG Group, Janssen Research & Development, MERCK, Novartis, Pfizer, Roche/Genentech and Seattle Genetics/Astellas. He has held a consulting or advisory role for AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Incyte, Ipsen, Merck, Novartis, Pfizer and Seattle Genetics. He has received research funding from AstraZeneca/MedImmune and Roche/Genentech and travel, accommodations and expenses from AstraZeneca, Bristol-Myers Squibb, Ferring, MSD, Novartis/Ipsen, Pfizer, Research to Practice and Roche/Genentech.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
Share this Video
Related Videos In Bladder Cancer
Thomas Powles, ASCO20: JAVELIN Bladder 100 Phase III Interim Analysis
It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Questions 1. What have we learned so far from clinical trials […]
Petros Grivas, ESMO 2019 – Advances in metastatic urothelial cancer
We joined Petros Grivas (University of Washington School of Medicine) at ESMO 2019 to discuss immune checkpoint inhibitors and novel agents in the treatment of metastatic urothelial cancer. Questions 1. How have immune checkpoint inhibitors changed the treatment landscape for metastatic urothelial cancer? (0:04) 2. What progress has been made in identifying biomarkers of response […]
Arlene Siefker-Radtke, ESMO 2019 – KEYNOTE-866 Phase III trial in bladder cancer
We are joined by Arlene Sietker-Radtke (The University of Texas MD Anderson Cancer Center) at ESMO 2019 to discuss her presentation on the results from the KEYNOTE-866 trial (NCT03924856). This phase III study investigates perioperative pembrolizumab or placebo in combination with neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer. Questions What are the limitations […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!